Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer
J Pan, J Wu, B Wang, B Zhu, X Liu, H Gan, Y Wei, S Jin… - Med, 2024 - cell.com
Background Interlesional response heterogeneity (ILRH) poses challenges to the treatment
of metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no …
of metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no …
激素敏感性前列腺癌患者中PSMA PET/CT 衍生参数与循环肿瘤DNA 特征之间的相关性分析
潘剑， 叶定伟， 朱耀， 王备合 - 中国癌症杂志, 2024 - china-oncology.com
背景与目的: 前列腺特异性膜抗原(prostate-specific membrane antigen, PSMA)
正电子发射计算机体层显像(positron emission tomography/computed tomography, PET/CT) …
正电子发射计算机体层显像(positron emission tomography/computed tomography, PET/CT) …
Correlation analysis of PSMA PET/CT-derived parameters and circulating tumor DNA features in patients with hormone-sensitive prostate cancer
PAN Jian, YE Dingwei, ZHU Yao, W Beihe - China Oncology, 2024 - china-oncology.com
Background and purpose: Both prostate-specific membrane antigen (PSMA) positron
emission tomography/computed tomography (PET/CT) and circulating tumor DNA (ctDNA) …
emission tomography/computed tomography (PET/CT) and circulating tumor DNA (ctDNA) …